周凤华, 贾钰华, 叶遂林, 娄林洁, 杨平, 李杰, 张月均, 钱荣江. 定心方联合胺碘酮治疗室性早搏:一项随机、双盲、多中心、安慰剂对照试验[J]. Digital Chinese Medicine, 2018, 1(1): 56-66.
引用本文: 周凤华, 贾钰华, 叶遂林, 娄林洁, 杨平, 李杰, 张月均, 钱荣江. 定心方联合胺碘酮治疗室性早搏:一项随机、双盲、多中心、安慰剂对照试验[J]. Digital Chinese Medicine, 2018, 1(1): 56-66.
ZHOU Feng-Hua, JIA Yu-Hua, YE Sui-Lin, LOU Lin-Jie, YANG Ping, LI Jie, ZHANG Yue-Jun, QIAN Rong-Jiang. A Chinese Compound Prescription Ding Xin Recipe Combined with Amiodarone for Treating Premature Ventricular Complexes: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Trial[J]. Digital Chinese Medicine, 2018, 1(1): 56-66.
Citation: ZHOU Feng-Hua, JIA Yu-Hua, YE Sui-Lin, LOU Lin-Jie, YANG Ping, LI Jie, ZHANG Yue-Jun, QIAN Rong-Jiang. A Chinese Compound Prescription Ding Xin Recipe Combined with Amiodarone for Treating Premature Ventricular Complexes: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Trial[J]. Digital Chinese Medicine, 2018, 1(1): 56-66.

定心方联合胺碘酮治疗室性早搏:一项随机、双盲、多中心、安慰剂对照试验

A Chinese Compound Prescription Ding Xin Recipe Combined with Amiodarone for Treating Premature Ventricular Complexes: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Trial

  • 摘要:
    目的 评估定心方(DXR)联合胺碘酮治疗室性早搏患者的疗效与安全性。
    方法 中国七所医院共360例室性早搏患者按1:1:1的比例随机分组,自2012年7月至2013年12月接受为期8周的临床治疗。根据独立指导委员会订制的中央随机化目录,将入组患者进行随机化分组,分为胺碘酮联合DXR安慰剂治疗组(胺碘酮组),DXR联合胺碘酮安慰剂治疗组(DXR组)与DXR联合胺碘酮治疗组(DCA组)。所有地点的工作人员和患者的治疗分配均不予告知,同时所有患者均收到最佳建议。主要结果为治疗室性早搏的疗效,通过减少室性早搏评估,其他结果指标测量包括与室性早搏相关的症状评分。所有数据均通过意向治疗进行分析。
    结果 与胺碘酮组(72.3%)与DXR组(73.9%)相比,DCA组治疗室性早搏的有效率(90.7%)显著增加,同时DCA组患者每周心悸、胸闷、气短与疲劳的频率、程度与持续时间明显改善(P < 0.05),但是三组之间在改善失眠方面没有显著差异(P > 0.05)。关于实验室安全参数方面,三组均无临床相关变化。
    结论 本研究表明DXR联合胺碘酮比单独使用DXR或胺碘酮治疗室性早搏更加有效。

     

    Abstract:
    Objective To evaluate the efficacy and safety of Ding Xin Recipe (DXR) combined with amiodarone in patients with PVCs.
    Methods A total of 360 patients with PVCs across 7 centers in China were randomly assigned in a 1:1:1 ratio to receive up to 8 weeks of amiodarone combined with DXR placebo (amiodarone group), DXR combined with amiodarone placebo (DXR group), or DXR combined with amiodarone (DCA group) from July 2012 to December 2013. Randomization was conducted according to a centralized randomization schedule prepared by an independent steering committee. Staff and patients at all sites were masked to treatment allocation. All patients received best-evidence advice. The primary outcome was the efficacy for treating PVCs, with efficacy assessed by the reduction of premature ventricular contractions. Other outcome measures included PVCs- related symptom scores. All data were analyzed by intention to treat.
    Results The efficacy for treating PVCs in the DCA group (90.7%) significantly increased compared with that in the amiodarone group (72.3%) and the DXR group (73.9%). The frequency, the degree, and the duration per week of heart palpitations, chest tightness, shortness of breath and fatigue improved significantly in the DCA group in comparison with the amiodarone group and the DXR group (P < 0.05), while no significant difference was observed in the improvement of insomnia among the three groups (P > 0.05). With regard to laboratory parameters for safety, there were no clinically relevant changes in the three groups.
    Conclusion The present study demonstrates that DXR combined with amiodarone is significantly more effective than DXR or amiodarone alone for treating PVCs.

     

/

返回文章
返回